MedTrace Logo

Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients

NCT04379037 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-06-04

No results posted yet for this study

Summary

This trial is designed to determine if the inflammation modulating effect of vagus nerve stimulation can improve pulmonary function and limit progression to ARDS in hospitalized COVID-19 hospitalized patients.

Conditions

  • Severe Acute Respiratory Syndrome Coronavirus 2

Interventions

DEVICE

Transcutaneous Auricular Vagus Nerve Stimulation

Transcutaneous vagus nerve stimulation involves stimulating the auricular branch of the vagus nerve with a imperceptible electrical current within the concha of the ear.

Sponsors & Collaborators

  • Nemechek Technologies

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-27
Primary Completion
2020-09-01
Completion
2020-11-01

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04379037 on ClinicalTrials.gov